BioCentury
ARTICLE | Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

How GammaDelta's 2017 $100 million option deal with Takeda fueled its multi-pronged pipeline strategy

July 19, 2019 12:38 AM UTC

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way.

Build-to-buy deal structures have recently fallen out of favor with some companies and investors, who cite the restrictions it can put on decision-making and financial returns, and a funding environment flush with venture capital making early-stage companies less reliant on pharma (see “Bye-Bye Build-to-Buy” and “Third Rock Keeps its Options Open”)...